论文部分内容阅读
我国己内酰胺产能明年将超过300万吨,产量过剩问题严重,产业结构调整势在必行。近几年中国己内酰胺行业迅速发展,随着鲁西化工、湖北三宁、山东方明、山东海力等新晋企业的新建产能投放,到2013年底国内己内酰胺产能达到181.5万吨/年。国内己内酰胺产能的大幅扩张,缓解了数年己内酰胺极度依赖进口的局面,同时由于产能不断增加,上下游发展的不平衡,己内酰胺行业营利空间将出现大幅度下降的趋势,产业布局和结构调整势在必行。年产能将超300万吨2013年底全球己内酰胺年产能达到645万吨,我国己内酰胺年产能达到
China’s caprolactam production capacity will exceed 3 million tons next year, and the problem of over-output will be serious. Adjustment of industrial structure is imperative. In recent years, the rapid development of China’s caprolactam industry, with Luxi Chemical, Hubei Sanning, Shandong Fangming, Shandong Haili and other emerging companies new production capacity put into operation, by the end of 2013 caprolactam production capacity reached 1,815,000 tons / year. The substantial expansion of domestic caprolactam production capacity has alleviated the situation that the caprolactam is extremely dependent on imports for several years. Meanwhile, due to the continuous increase of production capacity and unbalanced development of the upstream and downstream industries, the profit-making space of the caprolactam industry will see a drastic downward trend. The industrial layout and structural adjustment tend to be Will do. Annual production capacity will exceed 3 million tons By the end of 2013 the global annual production capacity of caprolactam reached 6.45 million tons, China’s annual production capacity of caprolactam